1,429 Amgen Inc. $AMGN Shares Sold by Citizens Financial Group Inc. RI

Citizens Financial Group Inc. RI trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 4.3% during the third quarter, Holdings Channel reports. The institutional investor owned 31,818 shares of the medical research company’s stock after selling 1,429 shares during the quarter. Citizens Financial Group Inc. RI’s holdings in Amgen were worth $13,412,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. State Street Corp grew its holdings in Amgen by 38.2% during the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock worth $15,283,363,000 after acquiring an additional 11,656,755 shares in the last quarter. Bank of America Corp DE purchased a new stake in shares of Amgen in the 2nd quarter valued at approximately $1,831,903,000. Wellington Management Group LLP increased its position in shares of Amgen by 1,102.7% in the 2nd quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company’s stock valued at $993,031,000 after purchasing an additional 2,514,254 shares during the last quarter. BlackRock Inc. increased its position in shares of Amgen by 4.8% in the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock valued at $17,874,974,000 after purchasing an additional 2,261,544 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in shares of Amgen by 702.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,535,257 shares of the medical research company’s stock valued at $647,126,000 after purchasing an additional 1,344,010 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares of the company’s stock, valued at $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Rachna Khosla sold 1,252 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,666,817.72. This represents a 16.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 6,222 shares of company stock worth $2,540,926 over the last quarter. 0.85% of the stock is owned by company insiders.

Amgen Stock Performance

Shares of Amgen stock opened at $439.26 on Friday. The firm has a market capitalization of $237.48 billion, a P/E ratio of 27.30, a P/E/G ratio of 3.22 and a beta of 0.41. Amgen Inc. has a 52 week low of $288.00 and a 52 week high of $450.98. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The firm’s 50 day moving average is $417.70 and its two-hundred day moving average is $377.83.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter last year, the company earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Research analysts forecast that Amgen Inc. will post 22.96 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 21st were given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend was Friday, August 21st. Amgen’s dividend payout ratio (DPR) is 62.65%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Jefferies Financial Group reaffirmed a “hold” rating and set a $410.00 price objective on shares of Amgen in a research report on Wednesday, September 23rd. Robert W. Baird boosted their target price on shares of Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 5th. Citigroup increased their target price on Amgen from $345.00 to $405.00 and gave the company a “neutral” rating in a report on Friday, August 7th. BMO Capital Markets cut their price target on Amgen from $450.00 to $415.00 and set a “market perform” rating on the stock in a research note on Monday, October 12th. Finally, Mizuho lifted their price target on Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a report on Tuesday, August 18th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $389.71.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Analyst remains bullish: Piper Sandler maintained its Buy rating and a $457 price target, implying continued confidence in Amgen’s earnings outlook, cash generation and pipeline. Piper Sandler Keeps Buy Rating on Amgen
• Positive Sentiment: Pipeline progress provides a potential catalyst: Amgen’s bemarituzumab study in gastric cancer has reached the Phase 3 finish line. While the report does not provide final efficacy or regulatory results, completion of the trial could eventually support a new oncology growth opportunity. Amgen Bemarituzumab Trial Update
• Neutral Sentiment: Tezspire update offers limited immediate clarity: Amgen reported results for Tezspire, but the available headline does not specify the clinical findings or their commercial implications. Investors will need additional detail to assess the impact on sales expectations. Amgen Reports Tezspire Results
• Negative Sentiment: Patent-cliff and dividend concerns are resurfacing: Coverage questions whether Amgen can protect its dividend when major products lose patent protection. The issue may weigh on the stock because investors are evaluating whether future cash flow can support both shareholder returns and replacement growth. Amgen Dividend and Patent Cliff Risks

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.